Investigational Drug Information for Carisbamate
✉ Email this page to a colleague
What is the development status for investigational drug Carisbamate?
Carisbamate is an investigational drug.
There have been 15 clinical trials for Carisbamate.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2009.
The most common disease conditions in clinical trials are Epilepsy, Epilepsies, Partial, and Seizures. The leading clinical trial sponsors are SK Life Science, Inc., SK Life Science, and PRA Health Sciences.
Summary for Carisbamate
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 144 |
| WIPO Patent Applications | 88 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 3 (2009-01-01) |
| Vendors | 30 |
Recent Clinical Trials for Carisbamate
| Title | Sponsor | Phase |
|---|---|---|
| Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | SK Life Science, Inc. | Phase 3 |
| Bioavailability and Food Effect Study of 3 Types of Carisbamate | PRA Health Sciences | Phase 1 |
| Bioavailability and Food Effect Study of 3 Types of Carisbamate | SK Life Science, Inc. | Phase 1 |
Clinical Trial Summary for Carisbamate
Top disease conditions for Carisbamate
Top clinical trial sponsors for Carisbamate
US Patents for Carisbamate
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
